Peritoneal Dialysis International最新文献

Rationale and design of the CORDIAL first-in-human clinical trial: A system for sorbent-assisted continuous flow peritoneal dialysis. 首次人体临床试验的原理和设计：吸收剂辅助连续流腹膜透析系统。

IF 3.7 3区医学

Peritoneal Dialysis International Pub Date : 2025-09-26 DOI: 10.1177/08968608251381933

Joost Christiaan de Vries, Maaike K van Gelder, Dian P Bolhuis, Frank Simonis, Marianne C Verhaar, María Auxiliadora Bajo Rubio, Gloria Del Peso, Rafael Selgas, Gabriele Donati, Giulia Ligabue, Gianni Cappelli, Karin Gf Gerritsen

{"title":"Rationale and design of the CORDIAL first-in-human clinical trial: A system for sorbent-assisted continuous flow peritoneal dialysis.","authors":"Joost Christiaan de Vries, Maaike K van Gelder, Dian P Bolhuis, Frank Simonis, Marianne C Verhaar, María Auxiliadora Bajo Rubio, Gloria Del Peso, Rafael Selgas, Gabriele Donati, Giulia Ligabue, Gianni Cappelli, Karin Gf Gerritsen","doi":"10.1177/08968608251381933","DOIUrl":"https://doi.org/10.1177/08968608251381933","url":null,"abstract":"Peritoneal dialysis (PD) has important disadvantages compared to hemodialysis, including low plasma clearance and limited technique survival. A new device for sorbent-assisted (continuous flow) peritoneal dialysis (SAPD) has been designed that is based on continuous recirculation of peritoneal dialysate via a single-lumen peritoneal catheter with regeneration of spent dialysate by sorbents. SAPD treatment may enhance plasma clearance of uremic solutes by increasing the mass transfer area coefficient and maintenance of a high plasma-to-dialysate concentration gradient. In addition, SAPD treatment may preserve integrity of the peritoneal membrane for a longer period of time by avoiding the need for high initial glucose concentrations and by reducing the number of exchanges and (dis)connections of the peritoneal catheter, which may lower the risk of peritonitis. The primary aim of this first-in-human clinical trial is to evaluate the (short-term) clinical safety and performance of SAPD treatment in a small group (n = 12) of stable adult PD patients in a clinical setting (proof of concept). Key secondary objectives include an evaluation of efficacy in terms of plasma clearance, ultrafiltration, and patient tolerance.","PeriodicalId":19969,"journal":{"name":"Peritoneal Dialysis International","volume":" ","pages":"8968608251381933"},"PeriodicalIF":3.7,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145150313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to 'Icodextrin lowers serum sodium in dose-dependent fashion: A case report': Keep calm and continue icodextrin. 对“依剂量降低血清钠：一例报告”的反应：保持冷静，继续服用依剂量降低血清钠。

IF 3.7 3区医学

Peritoneal Dialysis International Pub Date : 2025-09-26 DOI: 10.1177/08968608251381947

Jie Ming Nigel Fong, Pei Shan Lee

引用次数: 0

Reply to "Letter to Editor" titles as reflections on barriers to peritoneal dialysis (PD) utilization in South Asia: Towards sustainable solutions. 回复“致编辑的信”标题，反思南亚腹膜透析（PD）利用的障碍：走向可持续的解决方案。

IF 3.7 3区医学

Peritoneal Dialysis International Pub Date : 2025-09-25 DOI: 10.1177/08968608251381930

Priti Meena

引用次数: 0

External validation of a prognostic model in routine practice for short- and long-term survival in peritoneal dialysis. 腹膜透析患者短期和长期生存的预后模型的外部验证。

IF 3.7 3区医学

Peritoneal Dialysis International Pub Date : 2025-09-24 DOI: 10.1177/08968608251364097

Sara N Davison, Sarah Rathwell

{"title":"External validation of a prognostic model in routine practice for short- and long-term survival in peritoneal dialysis.","authors":"Sara N Davison, Sarah Rathwell","doi":"10.1177/08968608251364097","DOIUrl":"https://doi.org/10.1177/08968608251364097","url":null,"abstract":"BackgroundThere are several indices to predict survival at dialysis start but tools to predict mortality for prevalent patients are lacking. This study provides evidence for external validity of the Cohen model to assess 6-, 12-, and 18-months survival of prevalent peritoneal dialysis (PD) patients.MethodsProspective cohort study of 464 PD patients in a university-based program between 2015 and 2019. Survival probabilities were compared to observed survival. Discrimination and calibration were assessed through predicted risk-stratified observed survival, cumulative area under the curve, Somer's Dxy, and a calibration slope estimate.ResultsDiscrimination performance was moderate with c-statistic of 0.73 to 0.74 for all 3 time points. The model over predicted mortality risk with the best predictive accuracy for 6-month survival. The difference between observed and mean predicted survival at 6, 12, and 18 months was 3.1%, 5.5%, and 11.0%. Kaplan-Meier curves showed good discrimination between low- and high-risk patients with hazard ratios [95% confidence interval (CI)]: C4 vs C1 32.0 [4.3-236.5]. Miscalibration of the model was the greatest for the highest risk patient group in whom 12 and 18 months predicted survival was 15% and 28% lower than observed survival.ConclusionsThe Cohen prognostic model can identify PD patients at high risk for death over 6, 12, and 18 months. Given it overestimates mortality risk for the highest risk patients, care must be taken to not use predictions to withhold treatment but rather to risk stratify and identify those who may benefit from enhanced kidney supportive care. This miscalibration provides an imperative to refine the tool for PD patients.","PeriodicalId":19969,"journal":{"name":"Peritoneal Dialysis International","volume":" ","pages":"8968608251364097"},"PeriodicalIF":3.7,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145131864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing renin angiotensin inhibitor use in peritoneal dialysis: A single-center Canadian quality improvement study. 优化肾素血管紧张素抑制剂在腹膜透析中的应用：一项加拿大单中心质量改善研究。

IF 3.7 3区医学

Peritoneal Dialysis International Pub Date : 2025-09-24 DOI: 10.1177/08968608251377253

Meera Shah, Arti Dhoot, Christopher Gayowsky, Mona Aflaki, Bourne Auguste

{"title":"Optimizing renin angiotensin inhibitor use in peritoneal dialysis: A single-center Canadian quality improvement study.","authors":"Meera Shah, Arti Dhoot, Christopher Gayowsky, Mona Aflaki, Bourne Auguste","doi":"10.1177/08968608251377253","DOIUrl":"https://doi.org/10.1177/08968608251377253","url":null,"abstract":"BackgroundRenin-angiotensin system inhibitors (RASi) offer important benefits for patients on peritoneal dialysis (PD), particularly in preserving residual kidney function and peritoneal membrane integrity. Despite these benefits, concerns about hyperkalemia and hypotension often limit clinical practice utilization.ObjectivesTo achieve a 20% increase in RASi utilization among eligible patients on PD at an academic hospital in Toronto, Canada through a quality improvement initiative.MethodsWe conducted a pre-intervention analysis through retrospective chart review from July 2022 to September 2023. We implemented a \"PD Passport,\" a clinical documentation tool used by clinic staff in each visit to highlight missed RASi prescription opportunities. The primary outcome measure was RASi utilization at 6-month post-implementation. Process measures included PD passport completion rates, while balancing measures tracked rates of symptomatic hypotension and hyperkalemia.ResultsAmong 63 patients on PD (mean age 58.7 years, 55.6% male), baseline RASi utilization was 41%. Following implementation, RASi utilization increased to 59% by October 2024, representing a 17% increase but falling short of the 20% target. There were no significant differences in mean systolic blood pressure (125.71 ± 4.19, 125.64 ± 7.02 mmHg; p = 0.653), mean serum potassium (4.34 mmol/L, 4.31 mmol/L; p = 0.662), and mean urine output (915.2 mL, 921.8 mL; p = 0.881) before and after the intervention.ConclusionsThe PD Passport initiative substantially increased RASi utilization by 17% without compromising patient safety, as evidenced by stable blood pressure and potassium levels. While falling slightly short of our 20% target, this structured documentation approach effectively bridges the gap between evidence and practice, demonstrating the value of targeted tools in enhancing guideline-concordant care for PD patients.","PeriodicalId":19969,"journal":{"name":"Peritoneal Dialysis International","volume":" ","pages":"8968608251377253"},"PeriodicalIF":3.7,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145131879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex-based variations in PD outcomes. PD结果的性别差异。

IF 3.7 3区医学

Peritoneal Dialysis International Pub Date : 2025-09-24 DOI: 10.1177/08968608251381956

Omer Faruk Akcay

引用次数: 0

Validating the standardised outcomes in nephrology-life participation (SONG-LP) measure in people receiving peritoneal dialysis: Rationale and process. 在接受腹膜透析的人群中验证肾脏学-生活参与（SONG-LP）测量的标准化结果：原理和过程。

IF 3.7 3区医学

Peritoneal Dialysis International Pub Date : 2025-09-18 DOI: 10.1177/08968608251376478

Cameron Thomas Burnett, Allison Jaure, Anastasia Hughes, Angela Ju, Martin Howell, Karine Manera, Melissa Cheetham, David Wayne Johnson, Martin Wilkie, Fiona Loud, Ana Figueiredo, Catherine Cheung, Daniel Schwartz, Helen Hurst, Janine Farragher, Jenny Shen, Rachael L Morton, Rachael C Walker, Rajnish Mehrotra, Thyago Moraes, Sarbjit Vanita Jassal, Yeoungjee Cho

{"title":"Validating the standardised outcomes in nephrology-life participation (SONG-LP) measure in people receiving peritoneal dialysis: Rationale and process.","authors":"Cameron Thomas Burnett, Allison Jaure, Anastasia Hughes, Angela Ju, Martin Howell, Karine Manera, Melissa Cheetham, David Wayne Johnson, Martin Wilkie, Fiona Loud, Ana Figueiredo, Catherine Cheung, Daniel Schwartz, Helen Hurst, Janine Farragher, Jenny Shen, Rachael L Morton, Rachael C Walker, Rajnish Mehrotra, Thyago Moraes, Sarbjit Vanita Jassal, Yeoungjee Cho","doi":"10.1177/08968608251376478","DOIUrl":"https://doi.org/10.1177/08968608251376478","url":null,"abstract":"Life participation has been identified as a critically important core outcome to be reported in all trials in people receiving peritoneal dialysis (PD). Life participation is defined as the ability to participate in meaningful activities such as work (e.g. employment, housework, study), family, social (e.g. time with friends) and leisure (travel, hobbies, exercise) activities. However, life participation is rarely and inconsistently reported in trials in PD. The standardised outcomes in nephrology-life participation (SONG-LP) instrument was validated in adult kidney transplant recipients and demonstrated internal consistency and test-retest reliability. In this article, we outline the rationale and process for validating the SONG-LP instrument in people receiving PD.","PeriodicalId":19969,"journal":{"name":"Peritoneal Dialysis International","volume":" ","pages":"8968608251376478"},"PeriodicalIF":3.7,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in sorbent peritoneal dialysis technologies: A narrative review. 吸附性腹膜透析技术的进展：述评。

IF 3.7 3区医学

Peritoneal Dialysis International Pub Date : 2025-09-18 DOI: 10.1177/08968608251371951

Susan Bríd McGrath, Pauline Kosalka, Marjorie W Foo, Htay Htay, Edwina A Brown, Karin Gf Gerritsen, Olof Heimbürger, Arsh K Jain

{"title":"Advances in sorbent peritoneal dialysis technologies: A narrative review.","authors":"Susan Bríd McGrath, Pauline Kosalka, Marjorie W Foo, Htay Htay, Edwina A Brown, Karin Gf Gerritsen, Olof Heimbürger, Arsh K Jain","doi":"10.1177/08968608251371951","DOIUrl":"https://doi.org/10.1177/08968608251371951","url":null,"abstract":"Sorbent peritoneal dialysis (SPD) removes a tidal volume of spent dialysate, passing it through sorbent layers before infusing replacement electrolytes and dextrose to regenerate dialysate. We examine the five devices using SPD in published literature, reviewing their design, dialysis clearance, and ultrafiltration (UF) capacity-Automated Wearable Artificial Kidney (AWAK), now called Viva Kompact since 2024, Carry Life System PD/Carry Life UF, Wearable Artificial Kidney (WEAKID), Vicenza Wearable Artificial Kidney (ViWAK), and Renart-PD. Carry Life devices and Viva Kompact have reported on human trials, WEAKID and Renart-PD on animal studies, while ViWAK has published in vitro data. All devices have published data on dialysis clearance capabilities. WEAKID and Carry Life PD achieved a high dialysate:plasma concentration gradient for small solutes. Viva Kompact and Renart-PD reported stable or lower serum concentrations of urea, creatinine, phosphate, and β2-microglogulin following treatments. ViWAK demonstrated removal of creatinine, B2 microglobulin, and angiogenin to <10% of pre-treatment levels. UF capacity remains unknown for many devices. In human trials, Carry Life UF has achieved 863 mL UF in a 5-h treatment with the addition of 20 g/h of glucose to 1.5% dextrose dialysate. Viva Kompact has demonstrated 877 mL UF in a 9-h treatment using 1.5% dextrose dialysate in an animal model, comparable to 10-h APD, with the addition of 6.6 g/h glucose. Both devices have demonstrated improved UF per gram of glucose used. The expected use of these devices varies greatly, from an adjunct to currently available treatments to a complete replacement for current modalities. Large-scale, human studies are needed to determine their role in the future of PD delivery.","PeriodicalId":19969,"journal":{"name":"Peritoneal Dialysis International","volume":" ","pages":"8968608251371951"},"PeriodicalIF":3.7,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Teaching peritoneal dialysis: A position paper for the International Society for Peritoneal Dialysis. 腹膜透析教学：国际腹膜透析学会立场文件。

IF 3.7 3区医学

Peritoneal Dialysis International Pub Date : 2025-09-18 DOI: 10.1177/08968608251375512

Josephine Sf Chow, Gillian Brunier, Ana E Figueiredo, Helen Hurst, Diana Perez Moran, Joanna Lee Neumann, Rajnish Mehrotra, Lily Mushahar, Trudi Fuge, Carla Maria Avesani, Ngar Yee Chow, David W Johnson

{"title":"Teaching peritoneal dialysis: A position paper for the International Society for Peritoneal Dialysis.","authors":"Josephine Sf Chow, Gillian Brunier, Ana E Figueiredo, Helen Hurst, Diana Perez Moran, Joanna Lee Neumann, Rajnish Mehrotra, Lily Mushahar, Trudi Fuge, Carla Maria Avesani, Ngar Yee Chow, David W Johnson","doi":"10.1177/08968608251375512","DOIUrl":"https://doi.org/10.1177/08968608251375512","url":null,"abstract":"Given the central importance of the peritoneal dialysis (PD) nurse in successfully training and supporting a patient with PD at home, as well as preventing complications as a result of the therapy, the International Society for Peritoneal Dialysis (ISPD) has provided guidance on the principles for training in two previous publications. Despite the lack of high certainty evidence in teaching PD, this ISPD 2025 Position Paper builds upon the two prior works to provide contemporary approaches to training a patient/care partner for PD to be performed at home, based upon an evolution in healthcare practices broadly and the cumulative evidence to support recommendations to date. A number of practice points have been provided. Suggestions are discussed on key areas in teaching PD which include: (a) Education, knowledge, skills and attributes for the PD nurse trainer; (b) Preparation for the training; (c) Methods of training/educational interventions; (d) Post training; and (e) Measures of outcomes. Areas for future research are suggested and include: best practices on educational interventions; knowledge and skills necessary for PD nurses; and how to best capture and measure the patient experience related to PD training.","PeriodicalId":19969,"journal":{"name":"Peritoneal Dialysis International","volume":" ","pages":"8968608251375512"},"PeriodicalIF":3.7,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

State- and end-stage renal disease-network determinants of peritoneal dialysis utilization in the United States: A multi-level Beta-regression analysis. 美国腹膜透析利用的状态和终末期肾病网络决定因素：一项多层次β回归分析。

IF 3.7 3区医学

Peritoneal Dialysis International Pub Date : 2025-09-04 DOI: 10.1177/08968608251370857

George Miller, Ahmad Alkhatib

{"title":"State- and end-stage renal disease-network determinants of peritoneal dialysis utilization in the United States: A multi-level Beta-regression analysis.","authors":"George Miller, Ahmad Alkhatib","doi":"10.1177/08968608251370857","DOIUrl":"https://doi.org/10.1177/08968608251370857","url":null,"abstract":"BackgroundChronic kidney disease and end-stage renal disease (ESRD) significantly burden the U.S. healthcare system. Despite its benefits, such as cost savings and increased autonomy, peritoneal dialysis (PD) is underutilized. This study examines how state and ESRD network-level variations impact PD utilization across the United States, addressing a gap in previous investigations that have not fully disentangled the effects of measurable patient-level factors from harder-to-capture influences.MethodsWe analyzed publicly available data from the United States Renal Data System, Centers for Medicare and Medicaid Services, and the U.S. Census Bureau covering 50 states and two territories (2015-2020). Multi-level Beta regression models assessed how state-level predictors are associated with PD utilization, accounting for state and network-level variations. Ranked random effects were compared to 2020 PD rates to identify overperforming or underperforming regions.ResultsBetween 2015 and 2020, PD utilization rose from 9.6% to 12.8%. The proportions of incident dialysis patients who were male, ≥ 65 years, and White, respectively, and dialysis facilities per 100,000 people did not significantly affect PD utilization, whereas population density was significantly negatively associated. The final model revealed that unmeasured variations in PD utilization were significantly explained by both state (intraclass correlation coefficient (ICC) = 0.47) and network (ICC = 0.53) factors.ConclusionThe chosen demographic, provider, and geographical factors explain only 18.5% of PD utilization. About half of the remaining variation resides at the state level and half at the ESRD network level, verifying the importance of unmeasured factors at both levels. We provide adjusted PD utilization rankings-identifying overperforming and underperforming states and networks-where future research can identify disparate effective and ineffective regional policies with the aim of optimizing PD uptake.","PeriodicalId":19969,"journal":{"name":"Peritoneal Dialysis International","volume":" ","pages":"8968608251370857"},"PeriodicalIF":3.7,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144993123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0